BR112015009037A2 - composição farmacêutica para uso no tratamento de infarto do miocárdio e uso de um peptídeo de fragmento de hmgb1 - Google Patents

composição farmacêutica para uso no tratamento de infarto do miocárdio e uso de um peptídeo de fragmento de hmgb1

Info

Publication number
BR112015009037A2
BR112015009037A2 BR112015009037A BR112015009037A BR112015009037A2 BR 112015009037 A2 BR112015009037 A2 BR 112015009037A2 BR 112015009037 A BR112015009037 A BR 112015009037A BR 112015009037 A BR112015009037 A BR 112015009037A BR 112015009037 A2 BR112015009037 A2 BR 112015009037A2
Authority
BR
Brazil
Prior art keywords
myocardial infarction
treatment
pharmaceutical composition
fragment peptide
peptide
Prior art date
Application number
BR112015009037A
Other languages
English (en)
Inventor
Tamai Katsuto
Miyagawa Shigeru
Kamata Sokichi
Yamazaki Takehiko
Kaneda Yasufumi
Sawa Yoshiki
Original Assignee
Genomix Co Ltd
Univ Osaka
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomix Co Ltd, Univ Osaka filed Critical Genomix Co Ltd
Publication of BR112015009037A2 publication Critical patent/BR112015009037A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4718—Cytokine-induced proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Abstract

abstract a fragment peptide having a proper length composed of a part of an hmgb1 protein was synthesized and the peptide was confirmed to exhibit therapeutic effects on myocardial infarction. resumo patente de invenção: "método para tratamento de infarto do miocárdio usando fragmento de hmgb1". a presente invenção refere-se a um peptídeo de fragmento tendo um comprimento apropriado composto de uma parte de uma proteína hmgb1 que foi sintetizado e o peptídeo foi confirmado exibir efeitos terapêuticos sobre infarto do miocárdio.
BR112015009037A 2012-10-25 2013-10-24 composição farmacêutica para uso no tratamento de infarto do miocárdio e uso de um peptídeo de fragmento de hmgb1 BR112015009037A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012235785 2012-10-25
PCT/JP2013/078758 WO2014065347A1 (ja) 2012-10-25 2013-10-24 Hmgb1断片を利用した新規心筋梗塞の治療法

Publications (1)

Publication Number Publication Date
BR112015009037A2 true BR112015009037A2 (pt) 2017-11-14

Family

ID=50544720

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015009037A BR112015009037A2 (pt) 2012-10-25 2013-10-24 composição farmacêutica para uso no tratamento de infarto do miocárdio e uso de um peptídeo de fragmento de hmgb1

Country Status (17)

Country Link
US (1) US9623078B2 (pt)
EP (1) EP2913058B1 (pt)
JP (1) JP6253589B2 (pt)
KR (1) KR102146815B1 (pt)
CN (1) CN104884076B (pt)
AU (1) AU2013335684B2 (pt)
BR (1) BR112015009037A2 (pt)
CA (1) CA2889275C (pt)
DK (1) DK2913058T3 (pt)
ES (1) ES2660420T3 (pt)
HK (2) HK1211488A1 (pt)
MX (1) MX361259B (pt)
PL (1) PL2913058T3 (pt)
RU (1) RU2647467C2 (pt)
SG (1) SG11201503236RA (pt)
TR (1) TR201802122T4 (pt)
WO (1) WO2014065347A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2722909A1 (en) 2008-04-30 2009-11-05 Genomix Co., Ltd. Method for collecting functional cells in vivo with high efficiency
AU2010312537A1 (en) 2009-10-28 2012-05-17 Genomix Co., Ltd. Tissue-regeneration promoter using recruitment of bone marrow mesenchymal stem cells and/or pluripotent stem cells in blood
PT3358011T (pt) 2011-04-26 2020-04-23 Univ Osaka Péptido para induzir a regeneração de um tecido e a sua utilização
RU2649069C2 (ru) 2012-10-25 2018-04-02 Дженомикс Ко., Лтд. Новый способ лечения повреждения спинного мозга с применением фрагмента hmgb1
AU2013335684B2 (en) 2012-10-25 2017-06-29 Osaka University Novel method for treating cardiac infarction using HMGB1 fragment
CA3051825A1 (en) * 2017-01-27 2018-08-02 StemRIM Inc. Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure
MX2019012014A (es) * 2017-04-07 2019-11-11 Stemrim Inc Medicina terapeutica para enfermedades fibrosas.
WO2018199107A1 (ja) * 2017-04-25 2018-11-01 塩野義製薬株式会社 組織再生を誘導するためのペプチドとその利用
US11298403B2 (en) * 2017-12-01 2022-04-12 StemRIM Inc. Therapeutic agent for inflammatory bowel disease
JP7386455B2 (ja) * 2018-02-08 2023-11-27 株式会社ステムリム 乾癬の治療薬
JP7405345B2 (ja) * 2018-10-05 2023-12-26 株式会社ステムリム 間葉系幹細胞の動員活性を有するペプチド
WO2020085506A1 (ja) 2018-10-25 2020-04-30 国立大学法人大阪大学 軟骨疾患の治療薬
AU2020385059A1 (en) 2019-11-12 2022-06-02 Oxford University Innovation Limited Polypeptides related to HMGB1 useful for promoting tissue regeneration, compositions comprising same, and uses thereof
RU2718912C1 (ru) * 2019-12-24 2020-04-15 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт общей патологии и физиологии" (ФГБНУ "НИИОПП") Способ лечения и профилактики инфаркта миокарда с патологией легких
JPWO2021215375A1 (pt) * 2020-04-20 2021-10-28
AU2022276188A1 (en) 2021-05-19 2023-12-14 Oxford University Innovation Limited Polypeptides related to hmgb1 useful for promoting tissue regeneration, compositions comprising same, and uses thereof
WO2024005133A1 (ja) * 2022-06-30 2024-01-04 国立大学法人大阪大学 半月板の治療薬

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5238680B2 (pt) 1972-12-27 1977-09-30
US5658894A (en) 1989-04-23 1997-08-19 The Trustees Of The University Of Pennsylvania Compositions for inhibiting restenosis
US5661127A (en) * 1995-05-01 1997-08-26 The Regents Of The University Of California Peptide compositions with growth factor-like activity
JP3018313B2 (ja) 1996-02-23 2000-03-13 雪印乳業株式会社 骨形成促進及び骨吸収防止剤
US20040031072A1 (en) 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
BR0012787A (pt) 1999-07-28 2002-07-30 Univ Leland Stanford Junior Agonistas de receptor de nicotina no recrutamento de célula tronco e de célula progenitora
EP1114862A3 (de) 1999-11-17 2003-08-06 Switch Biotech Aktiengesellschaft Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankungen sowie ihre Verwendung zur Identifizierung von pharmakologisch aktiven Substanzen
WO2001062895A2 (en) 2000-02-24 2001-08-30 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
JP3421741B2 (ja) 2000-05-18 2003-06-30 筑波大学長 人工骨髄、血球細胞の増殖方法
US7754217B2 (en) 2001-03-16 2010-07-13 Bio3 Research Srl HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases
DE10121254A1 (de) 2001-04-30 2002-11-07 Switch Biotech Ag MRP8/MRP14 Heterodimers oder seiner Einzelkomponenten alleine oder in Kombination zur Behandlung und/oder Prävention von Hauterkrankungen, Wunden und/oder Wundheilungsstörungen, die durch eine verringerte Menge an MRP8/MRP14 Heterodimeren gekennzeichnet sind
EP1390058A2 (en) 2001-04-30 2004-02-25 Switch Biotech Aktiengesellschaft Mrp8/mrp14 heterodimer, or its individual components in combination, for treating and/or preventing skin diseases, wounds and/or wound-healing disturbances
CA2447576C (en) 2001-05-15 2014-04-08 North Shore-Long Island Jewish Research Institute Use of hmg fragments as anti-inflammatory agents
US7220723B2 (en) 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
ITMI20011986A1 (it) 2001-09-25 2003-03-25 San Raffaele Centro Fond Metodo e composizione per l'attivazione di cellule presentanti l'antigene
WO2003043651A1 (en) 2001-11-19 2003-05-30 Kyowa Hakko Kogyo Co., Ltd. Drug mobilizing pluripotent stem cells from tissue into peripheral blood
CN1630526B (zh) 2001-12-07 2010-05-05 马克罗珀尔生物外科公司 用加工的脂肪抽吸细胞来治疗患者的系统和方法
RU2005102593A (ru) * 2002-07-03 2005-10-10 Фондационе Чентро Сан Раффаэле Дель Монте Табор (It) Применение hmgb1 при лечении повреждения ткани и/или для промотирования восстановления ткани
DE60327075D1 (de) 2002-07-05 2009-05-20 Univ Laval Der entzündungsreaktionen
GB0226251D0 (en) 2002-11-11 2002-12-18 San Raffaele Centro Fond Acetylated protein
WO2004046345A2 (en) 2002-11-20 2004-06-03 Critical Therapeutics, Inc. Use of hmgb fragments as anti-inflammatory agents
WO2004061456A2 (de) 2003-01-03 2004-07-22 Alcedo Biotech Gmbh Verwendungen von hmgb, hmgn, hmga proteinen
WO2004075855A2 (en) 2003-02-26 2004-09-10 Biomed Solutions, Llc Process for in vivo treatment of specific biological targets in bodily fluid
CA2520515C (en) 2003-03-28 2012-08-28 Universite Laval S100 protein as neutrophil activator for alleviating neutropenia in cancer treatment
US20050014255A1 (en) 2003-05-29 2005-01-20 Board Of Regents, The University Of Texas System Stem cells for clinical and commercial uses
WO2005025604A2 (en) 2003-09-10 2005-03-24 The General Hospital Corporation Use of hmgb and hmgb fragments to decrease specific immune response
ITRM20040058A1 (it) 2004-02-03 2004-05-03 Marco E Bianchi Inibitori ed antagonisti di hmgb1 in grado di regolare la proliferazione delle cellule muscolari lisce ed endoteliali.
US20090062187A1 (en) 2004-07-20 2009-03-05 Marco Bianchi Use of Hmgb1 for Wound Healing
MX2007001155A (es) 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
WO2006024547A2 (en) 2004-09-03 2006-03-09 Creabilis Therapeutics S.P.A. Protease resistant human and non-human hmgb1 box-a mutants and their therapeutic/diagnostic use
KR100593397B1 (ko) 2004-10-27 2006-06-28 한국원자력연구소 중배엽 줄기세포 및/또는 ｐ 물질을 함유하는 상처 치유또는 상처 치유 촉진제, 또는 세포 치료제
WO2006047820A1 (en) 2004-11-01 2006-05-11 Newsouth Innovations Pty Limited Use of calgranulin a and b in the promotion and inhibition of mineralized tissue formation
ITRM20050032A1 (it) 2005-01-21 2006-07-22 Marco E Bianchi Inibitori ed antagonisti di hmgb1 in grado di inibire la patogenesi e la progressione della malattia aterosclerotica.
JP5103626B2 (ja) 2005-01-27 2012-12-19 財団法人ヒューマンサイエンス振興財団 間葉系幹細胞を含む細胞シート
PT1893253E (pt) 2005-03-23 2010-08-24 Biosafe Sa Sistema integrado para recolher, processar e transplantar subconjuntos de células, incluindo células estaminais adultas, para medicina regenerativa
WO2006114805A2 (en) 2005-04-28 2006-11-02 Fondazione Centro San Raffaele Del Monte Tabor Use of hmgb2 and hmgb3 proteins for medical applications
WO2007015546A1 (ja) 2005-08-04 2007-02-08 Genomix Co., Ltd 間葉系幹細胞誘導剤及び組織再生促進剤並びに間葉系幹細胞の調製方法
WO2007031100A1 (en) 2005-09-14 2007-03-22 Ostini, Marco Active immunotherapy of life-threatening systemic inflammation
US7829097B2 (en) * 2006-02-06 2010-11-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of HMGB1 for protection against ischemia reperfusion injury
JP4982739B2 (ja) 2006-06-01 2012-07-25 国立大学法人 東京医科歯科大学 ポリグルタミン病の予防・治療剤
WO2008018641A1 (en) 2006-08-11 2008-02-14 Ono Pharmaceutical Co., Ltd. Monoclonal antibodies against stromal derived factor-1 (sdf-1)
CN101374538A (zh) 2006-10-30 2009-02-25 吉诺米克斯股份有限公司 损伤组织的功能再生促进药物
CA2722909A1 (en) 2008-04-30 2009-11-05 Genomix Co., Ltd. Method for collecting functional cells in vivo with high efficiency
AU2009240885A1 (en) 2008-04-30 2009-11-05 Genomix Co., Ltd. Pharmaceutical agent for promoting the functional regeneration of damaged tissue
WO2009133939A1 (ja) 2008-04-30 2009-11-05 株式会社ジェノミックス 末梢循環への骨髄由来多能性幹細胞動員薬
ES2609006T3 (es) 2009-10-16 2017-04-18 Rutgers, The State University Of New Jersey Procedimeinto de tratamiento de lesión crónica de tejido nervioso usando una estrategia de terapia celular
AU2010312537A1 (en) 2009-10-28 2012-05-17 Genomix Co., Ltd. Tissue-regeneration promoter using recruitment of bone marrow mesenchymal stem cells and/or pluripotent stem cells in blood
PT3358011T (pt) * 2011-04-26 2020-04-23 Univ Osaka Péptido para induzir a regeneração de um tecido e a sua utilização
CN102443064A (zh) 2011-11-03 2012-05-09 刘誉 一种基于凝血酶活性的双靶向作用的嵌合多肽及其应用
RU2649069C2 (ru) 2012-10-25 2018-04-02 Дженомикс Ко., Лтд. Новый способ лечения повреждения спинного мозга с применением фрагмента hmgb1
AU2013335684B2 (en) 2012-10-25 2017-06-29 Osaka University Novel method for treating cardiac infarction using HMGB1 fragment

Also Published As

Publication number Publication date
US9623078B2 (en) 2017-04-18
DK2913058T3 (en) 2018-02-19
CN104884076A (zh) 2015-09-02
RU2647467C2 (ru) 2018-03-15
RU2015119517A (ru) 2016-12-20
JP6253589B2 (ja) 2017-12-27
KR20150103660A (ko) 2015-09-11
HK1212887A1 (zh) 2016-06-24
HK1211488A1 (en) 2016-05-27
US20150273017A1 (en) 2015-10-01
EP2913058A4 (en) 2016-04-13
MX361259B (es) 2018-11-30
AU2013335684B2 (en) 2017-06-29
SG11201503236RA (en) 2015-06-29
TR201802122T4 (tr) 2018-03-21
ES2660420T3 (es) 2018-03-22
AU2013335684A1 (en) 2015-05-14
MX2015005252A (es) 2015-10-29
CA2889275C (en) 2021-06-15
EP2913058A1 (en) 2015-09-02
JPWO2014065347A1 (ja) 2016-09-08
WO2014065347A1 (ja) 2014-05-01
PL2913058T3 (pl) 2018-04-30
CA2889275A1 (en) 2014-05-01
EP2913058B1 (en) 2017-12-20
CN104884076B (zh) 2017-10-03
KR102146815B1 (ko) 2020-08-21

Similar Documents

Publication Publication Date Title
BR112015009037A2 (pt) composição farmacêutica para uso no tratamento de infarto do miocárdio e uso de um peptídeo de fragmento de hmgb1
CY1119435T1 (el) Σκευασμα για αντισωμα εναντι- αλφα4βητα7
BR112015021371A2 (pt) uso de agonistas de receptor de formil peptídeo 2 para tratar doenças inflamatórias oculares
BR112015022047A8 (pt) uso de uma composição compreendendo nanopartículas contendo um fármaco da família limo e uma albumina
BR112015027288A8 (pt) uso de uma dose de imunossupressor, composição de nanocarreadores sintéticos tolerogênicos e kit
BR112012018951C8 (pt) anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
BR112016012506A2 (pt) Combinações farmacêuticas, seus usos, e uso de um portador de dados
ECSP13012436A (es) ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
BR112015019064A8 (pt) uso de uma composição compreendendo nanopartículas compreendendo paclitaxel e uma albumina para o tratamento de melanoma e kit
BR112015026006A2 (pt) métodos para o tratamento de câncer com o uso de terapia de combinação com inibidor de cinase tor
EP3533461A3 (en) Prame derived peptides and immunogenic compositions comprising these
CY1119410T1 (el) Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (tfpi)
CY1122483T1 (el) Λυοφιλοποιημενες παρασκευες μελφαλανης φλουφεναμιδης
BR112012018947B1 (pt) anticorpo anti-caprin-1 monoclonal, composição farmacêutica, combinação farmacêutica e usos de uma composição farmacêutica, de um anticorpo e de uma combinação farmacêutica
CO6551683A2 (es) Tratamiento para trastornos gastrointestinales
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
BR112015021392A2 (pt) uso de agonistas do receptor de peptídeo formil 2 para tratar doenças dermatológicas
CL2015002733A1 (es) Composición farmacéutica de clorhidrato de s-cetamina.
BR112013029256A8 (pt) combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2
BR112015026247A8 (pt) composto em combinação com um análogo de citidina, composição farmacêutica que os compreende, uso dos mesmos e kit
BR112014008036A2 (pt) tratamento de rinite
BR112018005905A2 (pt) ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto?
BR112013019513A2 (pt) métodos para o tratamento de úlceras diabéticas do pé
CO2020010193A2 (es) Una composición farmacéutica para la anemia
BR112015001521A2 (pt) previsão de resposta ao tratamento para inibidor jak/stat

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B25D Requested change of name of applicant approved

Owner name: OSAKA UNIVERSITY (JP) ; STEMRIM INC. (JP)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]